Shopping Cart
- Remove All
Your shopping cart is currently empty
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | Inquiry | Backorder |
| Description | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody that can be combined with Paclitaxel for cancer research, particularly in studies of ovarian, primary peritoneal, or fallopian tube cancer [1] [2] [3]. |
| Cas No. | 1638338-43-8 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.